Kimball Electronics, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a KE research report →
Range $20 – $32
Price Chart
About the company
Kimball Electronics, Inc. specializes in providing comprehensive contract electronics manufacturing (CEM) and an array of diversified production solutions, catering to clients across the automotive, medical, industrial, and public safety sectors. Their extensive service portfolio encompasses initial design and development support, robust supply chain management, and agile rapid prototyping alongside streamlined product introduction capabilities.
- CEO
- Richard D. Phillips
- IPO
- 2014
- Employees
- 5,600
- HQ
- Jasper, IN, US
Get TickerSpark's AI analysis on KE
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $429.94M
- P/E
- 21.90
- Fwd P/E
- 12.80
- PEG
- -1.63
- P/S
- 0.30
- P/B
- 0.77
- EV/EBITDA
- 6.89
- Div Yield
- 0.00%
- Gross Margin
- 8.09%
- Op Margin
- 4.50%
- Net Margin
- 1.41%
- ROE
- 3.53%
- ROIC
- 3.04%
Latest fiscal year · YoY change
- Revenue
- $1.43B-3.7%
- Gross Profit
- $122.78M+17.6%
- Op Income
- $66.06M
- Net Income
- $27.96M+64.6%
- EPS
- $1.13+66.2%
- OCF Growth
- -60.7%
- FCF Growth
- -86.2%
- 52W High
- $32.00
- 52W Low
- $17.65
- 50D MA
- $25.06
- 200D MA
- $25.04
- Beta
- 1.19
- RSI (14)
- 26
- Avg Volume
- 216.69K
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Kimball Electronics delivered a solid fiscal Q1 2027 with 7% sales growth, stable gross margin, and raised confidence that full-year sales will land at the high end of guidance, led by stronger medical demand and the Helvoet acquisition.· November 5, 2026
- Net sales were $390.8 million, up 7% year over year; adjusted EPS was $0.25 versus $0.49 last year, pressured mainly by a much higher tax rate.
- Gross margin was 7.9%, flat year over year, while adjusted operating income was $17.0 million, or 4.3% of sales.
- Medical was the standout: sales rose 14% to $116 million, helped by 9% organic growth and Helvoet contribution.
- Management reiterated full-year sales guidance of $1.535 billion to $1.560 billion and now expects sales toward the high end of that range.
- Cash conversion days stayed at a multiyear best of 82, but operating cash flow was negative due to a planned inventory build and acquisition-related borrowing increased to $235.7 million.
Kimball reported first-quarter fiscal 2027 net sales of $390.8 million, up 7% year over year, including 3% organic growth, $12.4 million from Helvoet, and a 1% favorable FX impact. Adjusted gross margin was 7.9%, flat from last year; adjusted operating income was $17.0 million, or 4.3% of sales, versus $17.5 million and 4.8% a year ago; and adjusted net income was $6.1 million, or $0.25 per diluted share, versus $12.3 million, or $0.49, last year. For the full year, management reiterated sales guidance of $1.535 billion to $1.560 billion and expects sales at the high end of that range, with adjusted operating income at 4.4% to 4.7% of net sales and capital expenditures of $50 million to $60 million. Jana Croom said the full-year tax rate is expected to be in the low 30s excluding withholding taxes, and that the Indianapolis medical CDMO ramp should continue to weigh on margins in the near term before improving as volume builds.
Ric Phillips said the quarter showed a solid start to fiscal 2027, with sales growth across all verticals and strong traction in medical. He emphasized that Helvoet is fitting better than expected, customer interest is rising, and the combined medical CDMO platform is opening new synergies across Tilburg, Pune, Indianapolis, and the broader Kimball footprint. His tone was upbeat but measured, repeatedly noting that the medical ramp will take time even as the company sees new opportunities and expects the Indianapolis facility to start production in December.
Jana Croom focused on the mechanics behind the quarter: 7.9% gross margin, $27.6 million of adjusted EBITDA, $17.0 million of adjusted operating income, and $6.1 million of adjusted net income. She said the margin was held back by higher material component costs and the ramp of the Indianapolis medical CDMO, while SG&A rose to $13.9 million due to growth investments and Helvoet-related costs. On the balance sheet, she cited $72.8 million of cash, $19.3 million of operating cash outflow, $312.1 million of inventory, $235.7 million of borrowings, and $270.8 million of short-term liquidity; she also noted $3.1 million spent on buybacks and reaffirmed full-year capex of $50 million to $60 million.
Analysts pressed management on what is making Helvoet more attractive post-close, with Ric Phillips pointing to the talent, customer interest, and emerging synergy opportunities across the combined medical platform. Questions also focused on supply chain tightness and inventory build; Jana Croom said memory and electronic components remain tight, especially in autos and industrial, but the inventory increase was mainly tied to growth and longer lead times rather than a specific inflation issue. On the tax rate, Jana explained that Q1 included about $30 million of cash repatriation, which lifted the rate to 66.1%, and said the company expects low-30s for the rest of the year while actively working to bring it down.
The bull case from the call is that medical growth is accelerating and could be the main driver of the company’s mix and earnings over time. Management said core medical is coming in stronger than expected, open orders were up 16% year over year, and the new Indianapolis facility plus Helvoet are creating a broader platform for future revenue synergies. They also said full-year sales are trending toward the high end of guidance and cash conversion remains at a multiyear best.
The main risks highlighted were margin pressure from the Indianapolis ramp, higher component costs, and elevated taxes from the cash repatriation. Management also said automotive and industrial remain exposed to inflationary pressure and component tightness, while some verticals like North American climate control and North American EV-related automotive demand were weak. They acknowledged that building the medical CDMO takes time, so revenue from the new capacity will not translate immediately into higher profitability.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 97.6%
- Shares Outstanding
- 23.99M
- Float Shares
- 23.41M
of shares held by institutions
178 13F filers
Buy/sell ratio 1.33. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Blackrock, Inc. | 2.57M | ▲ 124.96K |
| Vanguard Group Inc | 2.00M | ▲ 48.46K |
| Dimensional Fund Advisors LP | 1.65M | ▼ 1.65K |
| American Century Companies Inc | 1.52M | ▲ 215.91K |
| Bank Of America Corp | 1.25M | ▲ 63.33K |
| Vanguard Capital Management LLC | 1.02M | ▼ 49.72K |
| Vanguard Portfolio Management LLC | 775.63K | ▼ 35.41K |
| Acadian Asset Management LLC | 738.49K | ▼ 233 |
| Geode Capital Management, LLC | 715.98K | ▲ 26.31K |
| Earnest Partners LLC | 536.56K | ▲ 17.71K |
| State Street Corp | 515.44K | ▼ 2.37K |
| Wellington Management Group Llp | 503.43K | ▲ 469.38K |
Held by 178 ETFs
Biggest fund positions in KE by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Nov 17, 26 | Sidelinger Rebecca | other | 7,599 |
| Nov 13, 26 | Sidelinger Rebecca | other | 0 |
| Nov 13, 26 | Holcomb Michele | other | 7,599 |
| Nov 13, 26 | Lampert Gregory J. | other | 12,032 |
| Nov 13, 26 | PHILLIPPY ROBERT J | other | 7,599 |
| Nov 13, 26 | Repplier Colleen C | other | 7,598 |
| Nov 13, 26 | THAXTON GREGORY A | other | 7,598 |
| Nov 13, 26 | Vadaketh Tom George | other | 12,411 |
| Nov 13, 26 | Van Deursen Holly | other | 7,599 |
| Nov 13, 26 | Phillips Richard D | other | 46,839 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our KE coverage
Recent articles, reports, and earnings notes.
No research on KE yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate KE report →Bear of the Day: Kimball Electronics (KE)
zacks.com · Nov 16
This Kimball Electronics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday
benzinga.com · Nov 12
Buy, Sell, or Hold? Thursday’s Top Upgrades and Downgrades: Advanced Micro Devices, Alibaba Group, Cleveland-Cliffs, Conoco Phillips, Diamondback Energy, General Mills, NVIDIA, Toyota, Wendy’s and More
247wallst.com · Nov 12
What Kimball Electronics (KE) Said on Its Q1 Earnings Call
marketbeat.com · Nov 6
Kimball Electronics, Inc. (KE) Q1 2027 Earnings Call Transcript
seekingalpha.com · Nov 5
Kimball Electronics (KE) Lags Q1 Earnings Estimates
zacks.com · Nov 4
Kimball Electronics Reports Q1 Results Highlighted by the Return to Top-Line Growth; Company Reiterates Guidance for Fiscal 2027 With Sales Expected at the High End of the Range
businesswire.com · Nov 4
Kimball Electronics, Inc. Announces Date For Reporting First Quarter Fiscal Year 2027 Financial Results
gurufocus.com · Oct 21
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.